Drugs / group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine
group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine
also known as
A1-AT · alpha-1-antitrypsin · Group A · Group A and C Meningococcal Polysaccharide Conjugate Vaccine · Group A and C Meningococcal Polysaccharide Vaccine · Group A, C, Y and W135 Meningococcal conjugate vaccine · inhaled Prolastin (nebulized alpha1-antitrypsin) · Nano-reinforced calcium hydroxide medicament · +1 more
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02481232 | Jun 2015 → Apr 2016 | meningococcal meningitis | Lanzhou Institute of Biological Products Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT01406509 | Aug → Nov 2011 | — | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06314685 | Dec 2021 → Aug 2024 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06653608 | Apr → Sep 2024 | acute apical periodontitis, dental pulp necrosis | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT03383939 | Jun 1996 → Sep 1999 | bronchiectasis | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06314659 Comparator | Sep 2021 → Dec 2024 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine | “The objective of this study is to evaluate the safety of the group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine.” NCT01406509 ↗ |
| Known as | A1-AT | “Aim: to investigate the influence of alpha1-antitrypsin (A1-AT) nebulization on levels of A1-AT in BAL and plasma in patients with stable bronchiectasis.” NCT03383939 ↗ |
| Known as | alpha-1-antitrypsin | “Alpha-1-antitrypsin (A1AT) is a protease inhibitor involved in protecting lung tissue from enzymes of inflammatory cells” NCT03383939 ↗ |
| Known as | Group A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03383939 ↗ |
| Known as | Group A and C Meningococcal Polysaccharide Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06314659 ↗ |
| Known as | Group A and C Meningococcal Polysaccharide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06314685 ↗ |
| Known as | Group A, C, Y and W135 Meningococcal conjugate vaccine | “Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population” NCT02481232 ↗ |
| Known as | inhaled Prolastin (nebulized alpha1-antitrypsin) | “inhaled Prolastin (nebulized alpha1-antitrypsin)” NCT03383939 ↗ |
| Known as | Nano-reinforced calcium hydroxide medicament | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06653608 ↗ |
| Known as | Prolastin | “The effects of inhaled A1AT (Prolastin) on BAL concentration of total and free NE and A1AT and inhibitory capacity of NE were assessed after one month of treatment in patients...” NCT03383939 ↗ |
| Action | Inhibit | “Alpha-1-antitrypsin (A1AT) is a protease inhibitor involved in protecting lung tissue from enzymes of inflammatory cells, including neutrophilic elastase” NCT03383939 ↗ |
| Modality | Vaccine | “Conjugate vaccine” NCT01406509 ↗ |
| Route | Inhaled | “inhaled A1AT 250mg diluted in 10ml 0.9% saline solution once a day for a month” NCT03383939 ↗ |